Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2026-01-02 @ 9:19 AM
Study NCT ID:
NCT02814669
Status:
COMPLETED
Last Update Posted:
2019-09-24
First Post:
2016-06-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-09-23
Start Date Type:
ACTUAL
Primary Completion Date:
2019-07-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-07-31
Completion Date Type:
ACTUAL
First Submit Date:
2016-06-20
First Submit QC Date:
None
Study First Post Date:
2016-06-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-09-23
Last Update Post Date:
2019-09-24
Last Update Post Date Type:
ACTUAL